MARKET

CBAY

CBAY

CymaBay
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.950
-0.070
-3.47%
Closed 19:36 01/21 EST
OPEN
2.060
PREV CLOSE
2.020
HIGH
2.110
LOW
1.950
VOLUME
1.50M
TURNOVER
--
52 WEEK HIGH
14.00
52 WEEK LOW
1.290
MARKET CAP
133.97M
P/E (TTM)
-1.3614
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CBAY and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 10 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CBAY News

  • Edited Transcript of CBAY earnings conference call or presentation 5-Nov-19 9:30pm GMT
  • Thomson Reuters StreetEvents.6d ago
  • CymaBay Therapeutics Enters Oversold Territory
  • Zacks.01/10 14:21
  • Citi Downgrades Intercept, Says NASH Launch Is Appropriately Priced In
  • Benzinga.01/02 17:40
  • These Falling Knives May Be Worth Catching
  • GuruFocus.com.12/31/2019 16:48

More

Industry

Biotechnology & Medical Research
-0.61%
Pharmaceuticals & Medical Research
-0.39%

Hot Stocks

Name
Price
%Change

About CBAY

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company's product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout. MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta (PPARd). The Company has completed over five Phase I clinical studies and a Phase II clinical study for MBX-8025. MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes (T2DM), with a dual mechanism, including direct effects and indirect effects mediated by gastrointestinal hormones known as incretins on glucose-dependent insulin secretion, as well as potentially beneficial effects on islet health. The Company has completed over four Phase I clinical studies and a Phase II clinical study for MBX-2982.
More

Webull offers CymaBay Therapeutics Inc (CBAY) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.